Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis

• Market Cap: ₹35.26B
• Dividend Yield: 0.03%
• Average Volume (3M): 2.36K
• Price to Earnings (P/E): 57.0
• Beta (1Y): 0.94
• Revenue Growth: 2.37%
• EPS Growth: -30.78%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.30
• Shares Outstanding: 100,282,510
• 10 Day Avg. Volume: 2,111
• 30 Day Avg. Volume: 2,356
• PEG Ratio: -2.39
• Price to Book (P/B): 5.63
• Price to Sales (P/S): 4.13
• P/FCF Ratio: 124.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹373.00
• Price Target Upside: 6.07% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: ₹373.00 ▲(6.07% Upside)

Gufic Biosciences' overall score is driven by solid financial performance and stable balance sheet, though tempered by high valuation and lack of strong market momentum. The absence of earnings call data and corporate events leaves these areas unassessed.

Gufic Biosciences Limited Business Overview & Revenue Model

Company Description

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.

How the Company Makes Money

Gufic Biosciences Limited generates revenue primarily through the manufacturing and sale of pharmaceutical products. The company's revenue streams include formulations, which encompass a wide range of therapeutic segments such as anti-infectives, critical care, and dermatology. Additionally, Gufic produces active pharmaceutical ingredients (APIs) which are sold to other pharmaceutical companies for drug manufacturing. The company also has a presence in the herbal and consumer healthcare space, offering products that cater to wellness and preventive care. Partnerships with hospitals and healthcare providers, along with a robust distribution network, play a significant role in the company's revenue generation strategy.

Gufic Biosciences Limited Financial Statement Overview

Summary

Gufic Biosciences shows strong revenue growth and operational efficiency, but faces challenges with net income volatility and inconsistent cash flow performance. The balance sheet is stable but requires careful debt management.

Income Statement

Gufic Biosciences has demonstrated strong revenue growth over the years, with a notable increase in total revenue from 2020 to 2025. The gross profit margin and EBIT margin are solid, indicating efficient cost management and operational effectiveness. However, the net profit margin has shown some fluctuations, suggesting potential volatility in net income performance.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position with a consistent increase in stockholders' equity. However, the debt-to-equity ratio is moderately high, which may pose risks if not managed carefully. The equity ratio shows a healthy proportion of equity in the capital structure, enhancing financial stability.

Cash Flow

Gufic Biosciences exhibits inconsistent free cash flow performance, with notable fluctuations in free cash flow growth rates. The operating cash flow to net income ratio shows variability, suggesting challenges in converting income into cash flow. Despite periods of negative free cash flow, recent improvements indicate potential for recovery.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.41B	8.20B	8.07B	6.91B	7.79B	4.88B
Gross Profit	4.17B	2.97B	4.07B	3.51B	3.56B	2.31B
EBITDA	1.36B	1.38B	1.48B	1.37B	1.48B	857.85M
Net Income	618.64M	696.50M	861.36M	797.05M	958.40M	442.32M
Balance Sheet
Total Assets	0.00	11.69B	10.93B	8.61B	5.21B	3.92B
Cash, Cash Equivalents and Short-Term Investments	290.22M	290.22M	11.37M	286.02M	116.08M	62.01M
Total Debt	0.00	3.36B	3.33B	3.34B	643.87M	615.37M
Total Liabilities	-6.01B	5.68B	5.60B	5.13B	2.52B	2.19B
Stockholders Equity	6.01B	6.01B	5.33B	3.48B	2.69B	1.73B
Cash Flow
Free Cash Flow	0.00	270.96M	-1.20B	-2.14B	187.86M	748.51M
Operating Cash Flow	0.00	1.03B	-74.57M	-265.87M	1.06B	872.51M
Investing Cash Flow	0.00	-717.09M	-1.02B	-1.91B	-945.89M	-66.93M
Financing Cash Flow	0.00	-163.26M	823.81M	2.34B	-62.44M	-786.18M

Gufic Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 351.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Negative. The current price of 351.65 is below the 20-day moving average (MA) of 360.95, below the 50-day MA of 362.94, and below the 200-day MA of 375.94, indicating a bearish trend. The MACD of -1.64 indicates Positive momentum. The RSI at 40.92 is Neutral, neither overbought nor oversold. The STOCH value of 25.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GUFICBIO.

Gufic Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOREPENLAB	67 Neutral	₹26.37B	28.24	―	0.42%	2.12%	-25.99%
ORCHPHARMA	58 Neutral	₹36.87B	43.26	―	―	-3.45%	-23.60%
GUFICBIO	57 Neutral	₹35.26B	57.00	―	0.03%	2.37%	-30.78%
IOLCP	56 Neutral	₹28.62B	27.25	―	0.82%	2.73%	-11.40%
HIKAL	55 Neutral	₹29.58B	46.73	―	0.58%	1.67%	-6.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	45 Neutral	₹26.35B	96.22	―	0.07%	-8.28%	-246.17%